# Open Orphan potential catalysts and returns for investors Q&A (LON:ORPH)

- Link: https://www.directorstalkinterviews.com/open-orphan-potential-catalysts-and-returns-for-investors-qa-lonorph/4121056047
- Published: 2022-03-09T07:29:11+00:00
- Author: Giles

Following the **Open Orphan plc** ([LON:ORPH](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l))
trading update we caught up with Arden Partners Head of Research Andrew Simms for
his thoughts.

**Open Orphan has released a trading update for the full year 2021, what were the
key highlights?**

The trading update for the 2021 full year indicated trading in line with management
expectations and guidance. In addition, 2022 is expected to be inline with management
expectations. Considering the nature of the Group’s business and visibility over
2022 forecasts in a structurally growing and non-economically sensitive industry,
this is encouraging. The announcement of expansion in patient screening also frees
up capacity to expand services and better manage facilities to support efficiency
improvements over time.

**How do you view the company outlook?**

Previous comments from the Company indicated that 95% of 2022 forecasted contracts
had been signed. FY22 numbers are well underpinned and further growth in the pipeline
from what is a very active vaccine development market and resulting pipeline conversion
over the next 3-6 months supports the Company’s outlook.

**In terms of an investment how do you view the company?**

The stock’s recent underperformance of the market does not reflect the Group’s infectious
disease research and development exposure and potential improving consistency, recurring
revenue and margin improvements. Possible monetisation of non-core assets also provides
further potential catalysts and returns for investors.

**Open Orphan plc** ([LON: ORPH](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l))
is a rapidly growing niche CRO pharmaceutical services company which is a world 
leader in the testing of vaccines and antivirals through the use of human challenge
clinical trials.

Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO
and Venn Life Sciences.

Share on:
